고바이오랩

348150KOSDAQ

46.0 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 8.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

KobioLab is a global biotech company leading the development of microbiome-based therapeutics, with a diverse pipeline targeting immune, metabolic, and neurological disorders. Utilizing its proprietary Smartiome platform, the company is conducting global clinical trials and has expanded into the functional food market through its subsidiary, Wibiome.

Number of Employees

57people

Average Salary

57.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.15Industry Average 1.204.0Point

In line with industry avg

ROE

-13.31Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

58.16Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲53.8% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲11.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.5% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 2,910Won52-week high 6,72052-week low 2,655

1-month return1.0Point

1m -8.06% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-13